{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:29:46Z","timestamp":1784258986599,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,1,4]],"date-time":"2015-01-04T00:00:00Z","timestamp":1420329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12020-014-0503-8","type":"journal-article","created":{"date-parts":[[2015,1,3]],"date-time":"2015-01-03T08:20:58Z","timestamp":1420273258000},"page":"683-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice"],"prefix":"10.1007","volume":"49","author":[{"given":"Xianlong","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasool Lubna","family":"Muhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,4]]},"reference":[{"key":"503_CR1","doi-asserted-by":"crossref","first-page":"34559","DOI":"10.1074\/jbc.M111.285965","volume":"286","author":"W Chen","year":"2011","unstructured":"W. Chen, R.L. Hoo, M. Konishi, N. Itoh, P.C. Lee, H.Y. Ye et al., Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J. Biol. Chem. 286, 34559\u201334566 (2011)","journal-title":"J. Biol. Chem."},{"key":"503_CR2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","volume":"115","author":"A Kharitonenkov","year":"2005","unstructured":"A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath et al., FGF-21 as a novel metabolic regulator. J. Clin. Inves. 115, 1627\u20131635 (2005)","journal-title":"J. Clin. Inves."},{"key":"503_CR3","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","volume":"55","author":"W Wente","year":"2006","unstructured":"W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. K\u00f6ster, G.E. Sandusky et al., Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways. Diabetes 55, 2470\u20132478 (2006)","journal-title":"Diabetes"},{"key":"503_CR4","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","volume":"45","author":"X Huang","year":"2006","unstructured":"X. Huang, C. Yu, C. Jin, C. Yang, R. Xie, D. Cao et al., Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol. Carcinog. 45, 934\u2013942 (2006)","journal-title":"Mol. Carcinog."},{"key":"503_CR5","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","volume":"149","author":"T Coskun","year":"2008","unstructured":"T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen et al., FGF21 corrects obesity in mice. Endocrinology 149, 6018\u20136127 (2008)","journal-title":"Endocrinology"},{"key":"503_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits et al., FGF21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250\u2013259 (2009)","journal-title":"Diabetes"},{"key":"503_CR7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","volume":"148","author":"A Kharitonenkov","year":"2007","unstructured":"A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno et al., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148, 774\u2013781 (2007)","journal-title":"Endocrinology"},{"key":"503_CR8","doi-asserted-by":"crossref","first-page":"e49345","DOI":"10.1371\/journal.pone.0049345","volume":"7","author":"R Hecht","year":"2012","unstructured":"R. Hecht, Y.S. Li, J. Sun, E. Belouski, M. Hall, T. Hager et al., Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 7, e49345 (2012)","journal-title":"PLoS ONE"},{"key":"503_CR9","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1021\/bc060245m","volume":"18","author":"BK Lee","year":"2007","unstructured":"B.K. Lee, J.S. Kwon, H.J. Kim, S. Yamamoto, E.K. Lee, Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem. 18, 1728\u20131734 (2007)","journal-title":"Bioconjug. Chem."},{"key":"503_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1386207053258578","volume":"8","author":"Y Mukai","year":"2005","unstructured":"Y. Mukai, Y. Yoshioka, Y. Tsutsumi, Phage display and PEGylation of therapeutic proteins. Comb. Chem. High Throughput Screen 8, 145\u2013152 (2005)","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"503_CR11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451\u20131458 (2005)","journal-title":"Drug Discov. Today"},{"key":"503_CR12","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","volume":"252","author":"A Abuchowski","year":"1977","unstructured":"A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, F.F. Davis, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582\u20133586 (1977)","journal-title":"J. Biol. Chem."},{"key":"503_CR13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bioeng.2007.10.002","volume":"24","author":"Q An","year":"2007","unstructured":"Q. An, Y. Lei, N. Jia, X. Zhang, Y. Bai, J. Yi et al., Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomol. Eng. 24, 643\u2013649 (2007)","journal-title":"Biomol. Eng."},{"key":"503_CR14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","volume":"14","author":"X Ye","year":"2013","unstructured":"X. Ye, J. Qi, G. Sun, G. Ren, S. Zhu, Y. Wu et al., Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation. Curr. Pharm. Biotechnol. 14, 1287\u20131298 (2013)","journal-title":"Curr. Pharm. Biotechnol."},{"key":"503_CR15","doi-asserted-by":"crossref","first-page":"e20669","DOI":"10.1371\/journal.pone.0020669","volume":"6","author":"Z Huang","year":"2011","unstructured":"Z. Huang, H. Wang, M. Lu, C. Sun, X. Wu, Y. Tan et al., A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 6, e20669 (2011)","journal-title":"PLoS ONE"},{"key":"503_CR16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, P. Raskin et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met\u00a0+\u00a0TZD). Diabet. Care 32, 1224\u20131230 (2009)","journal-title":"Diabet. Care"},{"key":"503_CR17","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","volume":"52","author":"D Russell-Jones","year":"2009","unstructured":"D. Russell-Jones, A. Vaag, O. Schmitz, B.K. Sethi, N. Lalic, S. Antic et al., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met\u00a0+\u00a0SU): a randomised controlled trial. Diabetologia 52, 2046\u20132055 (2009)","journal-title":"Diabetologia"},{"key":"503_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","volume":"26","author":"M Marre","year":"2009","unstructured":"M. Marre, J. Shaw, M. Br\u00e4ndle, W.M. Bebakar, N.A. Kamaruddin, J. Strand et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26\u00a0weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26, 268\u2013278 (2009)","journal-title":"Diabet. Med."},{"key":"503_CR19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"M. Nauck, A. Frid, K. Hermansen, N.S. Shah, T. Tankova, I.H. Mitha et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabet. Care 32, 84\u201390 (2009)","journal-title":"Diabet. Care"},{"key":"503_CR20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett et al., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39\u201347 (2009)","journal-title":"Lancet"},{"key":"503_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"A. Garber, R. Henry, R. Ratner, P.A. Garcia-Hernandez, H. Rodriguez-Pattzi, I. Olvera-Alvarez et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473\u2013481 (2009)","journal-title":"Lancet"},{"key":"503_CR22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381, 117\u2013124 (2013)","journal-title":"Lancet"},{"key":"503_CR23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","volume":"45","author":"H Agers\u00f8","year":"2002","unstructured":"H. Agers\u00f8, L.B. Jensen, B. Elbr\u00f8nd, P. Rolan, M. Zdravkovic, The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45, 195\u2013202 (2002)","journal-title":"Diabetologia"},{"key":"503_CR24","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3724\/SP.J.1206.2009.00238","volume":"36","author":"MY Liu","year":"2009","unstructured":"M.Y. Liu, W.F. Wang, Y.X. Yu, Y.T. Hou, G.P. Ren, D.S. Li, FGF21 improves glucose uptake and glycogen synthesis of insulin-resistant liver cells. Prog. Biochem. Biophys. 36, 1327\u20131333 (2009)","journal-title":"Prog. Biochem. Biophys."},{"key":"503_CR25","doi-asserted-by":"crossref","first-page":"e40164","DOI":"10.1371\/journal.pone.0040164","volume":"7","author":"MM V\u00e9niant","year":"2012","unstructured":"M.M. V\u00e9niant, C. Hale, J. Helmering, M.M. Chen, S. Stanislaus, J. Busby et al., FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS ONE 7, e40164 (2012)","journal-title":"PLoS ONE"},{"key":"503_CR26","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc09-S062","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabet. Care 32, S62\u2013S67 (2009)","journal-title":"Diabet. Care"},{"key":"503_CR27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.clinthera.2007.06.018","volume":"29","author":"A Barnett","year":"2007","unstructured":"A. Barnett, Dosing of insulin glargine in the treatment of type 2 diabetes. Clin. Ther. 29, 987\u2013999 (2007)","journal-title":"Clin. Ther."},{"key":"503_CR28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1463-1326.2000.00085.x","volume":"2","author":"JE Gerich","year":"2000","unstructured":"J.E. Gerich, Physiology of glucose homeostasis. Diabet. Obes. Metab. 2, 345\u2013350 (2000)","journal-title":"Diabet. Obes. Metab."},{"key":"503_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Holman, R. Sherwin et al., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabet. Care 32, 193\u2013203 (2009)","journal-title":"Diabet. Care"},{"key":"503_CR30","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","volume":"31","author":"E Montanya","year":"2009","unstructured":"E. Montanya, G. Sesti, A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin. Ther. 31, 2472\u20132488 (2009)","journal-title":"Clin. Ther."},{"key":"503_CR31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.clinthera.2013.03.021","volume":"35","author":"M Malmen\u00e4s","year":"2013","unstructured":"M. Malmen\u00e4s, J.R. Bouchard, J. Langer, Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8\u00a0mg or twice-daily exenatide 10 \u03bcg. Clin. Ther. 35, 795\u2013807 (2013)","journal-title":"Clin. Ther."},{"key":"503_CR32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01356.x","volume":"13","author":"A Garber","year":"2011","unstructured":"A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, B. Bode et al., Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2\u00a0years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabet. Obes. Metab. 13, 348\u2013356 (2011)","journal-title":"Diabet. Obes. Metab."},{"key":"503_CR33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00125-011-2069-9","volume":"54","author":"M Shimoda","year":"2011","unstructured":"M. Shimoda, Y. Kanda, S. Hamamoto, K. Tawaramoto, M. Hashiramoto, M. Matsuki et al., The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 54, 1098\u20131108 (2011)","journal-title":"Diabetologia"},{"key":"503_CR34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3892\/ijmm.2013.1453","volume":"32","author":"LN Chen","year":"2013","unstructured":"L.N. Chen, J. Lyu, X.F. Yang, W.J. Ji, B.X. Yuan, M.X. Chen et al., Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice. Int. J. Mol. Med. 32, 892\u2013900 (2013)","journal-title":"Int. J. Mol. Med."},{"key":"503_CR35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-924230","volume":"114","author":"MA Nauck","year":"2006","unstructured":"M.A. Nauck, M. Hompesch, R. Filipczak, T.D. Le, M. Zdravkovic, J. Gumprecht et al., Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 114, 417\u2013423 (2006)","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"503_CR36","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1210\/en.2009-0221","volume":"150","author":"ED Berglund","year":"2009","unstructured":"E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, A.B. Shanafelt et al., Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150, 4084\u20134093 (2009)","journal-title":"Endocrinology"},{"key":"503_CR37","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout et al., Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc. Natl. Acad. Sci. USA 109, 3143\u20133148 (2012)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"503_CR38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.peptides.2013.11.011","volume":"52","author":"Y Shao","year":"2014","unstructured":"Y. Shao, G. Yuan, Y. Feng, J. Zhang, X. Guo, Early liraglutide treatment is better in glucose control, \u03b2-cell function improvement and mass preservation in db\/db mice. Peptides 52, 134\u2013142 (2014)","journal-title":"Peptides"},{"key":"503_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.regpep.2010.07.110","volume":"164","author":"RC Moffett","year":"2010","unstructured":"R.C. Moffett, S. Patterson, P.R. Flatt, Effects of Liraglutide on glycaemic control and pancreatic islet morphology in C57BL\/KsJ db\/db mice with degenerative diabetes. Regul. Pept. 164, 43 (2010)","journal-title":"Regul. Pept."},{"key":"503_CR40","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/gut.2009.199661","volume":"59","author":"F Stickel","year":"2010","unstructured":"F. Stickel, C. Hellerbrand, Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59, 1303\u20131307 (2010)","journal-title":"Gut"},{"key":"503_CR41","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2004-1024","volume":"90","author":"F Angelico","year":"2005","unstructured":"F. Angelico, M. Del Ben, R. Conti, S. Francioso, K. Feole, S. Fiorello et al., Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 90, 1578\u20131582 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"503_CR42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","volume":"16","author":"European Diabetes Policy Group","year":"1999","unstructured":"European Diabetes Policy Group, A desktop guide to Type 2 diabetes mellitus. Diabet. Med. 16, 716\u2013730 (1999)","journal-title":"Diabet. Med."},{"key":"503_CR43","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc07-S004","volume":"30","author":"American Diabetes Association","year":"2007","unstructured":"American Diabetes Association, Standards of medical care in diabetes\u20142007. Diabet. Care 30, S4\u2013S41 (2007)","journal-title":"Diabet. Care"},{"key":"503_CR44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1262-3636(07)70133-7","volume":"30","author":"C Postic","year":"2004","unstructured":"C. Postic, R. Dentin, J. Girard, Role of the liver in the control of carbohydrate and lipid homeostasis. Diabet. Metab. 30, 398\u2013408 (2004)","journal-title":"Diabet. Metab."},{"key":"503_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2337\/db08-1470","volume":"58","author":"L Agius","year":"2009","unstructured":"L. Agius, Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 58, 18\u201320 (2009)","journal-title":"Diabetes"},{"key":"503_CR46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jcp.24133","volume":"228","author":"L Lu","year":"2013","unstructured":"L. Lu, C.P. Seidel, T. Iwase, R.K. Stevens, Y.Y. Gong, X. Wang et al., Suppression of GLUT1; a new strategy to prevent diabetic complications. J. Cell. Physiol. 228, 251\u2013257 (2013)","journal-title":"J. Cell. Physiol."},{"key":"503_CR47","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1172\/JCI117733","volume":"95","author":"BA Haber","year":"1995","unstructured":"B.A. Haber, S. Chin, E. Chuang, W. Buikhuisen, A. Naji, R. Taub, High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes. J. Clin. Invest 95, 832\u2013841 (1995)","journal-title":"J. Clin. Invest"},{"key":"503_CR48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF01616377","volume":"11","author":"K Prasad","year":"2007","unstructured":"K. Prasad, Suppression of phosphoenolpyruvate carboxykinase gene expression by secoisolariciresinol diglucoside (SDG), a new antidiabetic agent. Int. J. Angiol. 11, 107\u2013109 (2007)","journal-title":"Int. J. Angiol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0503-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-014-0503-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0503-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T22:21:08Z","timestamp":1650925268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-014-0503-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,4]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1007\/s12020-014-0503-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,4]]}}}